KRT19 and cancer: In pre-menopausal subgroup analysis, CK19 > 3.3 ng/ml (p = 0.007, OR = 11.541, 95%CI 1.968–67.668), type II cancer (p = 0.017, OR = 8.336, 95%CI 1.456–47.722) and ROMA% value (p = 0.001, OR = 0.955, 95%CI 0.929–0983) were testified to be independent risk factors for ovarian metastasis, both through univariate (Supplementary Table 2) and multivariate analysis (Table 3).